Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial.

All laromestrocel groups showed a trend toward improvement in the MoCA (Fig. 2b and Supplementary Table 4 ) and MMSE-2 (Fig. 2c and Supplementary Table 5 ) scores compared to placebo ( n = 10) at week 39, reaching statistical significance for the MoCA in group 2 (25 M × 1; P = 0.009; n = 11) and for the combined treatment effect group (groups 2–4, P = 0.015; n = 32).

also in 53,322 other papers

The left medial temporal cortex also showed progressive improvement at week 39 versus placebo; while reduced atrophy in group 2 did not reach statistical significance, the higher-dosage groups 3 and 4 demonstrated significant reduction in atrophy relative to placebo ( n = 10) (group 3, P = 0.001, n = 11; group 4, P = 0.032, n = 10) (Fig. 3g ).

also in 111,027 other papers